Acorda Therapeutics’ Online Multiple Sclerosis Resources To Be Demonstrated in Dallas

Maureen Newman avatar

by Maureen Newman |

Share this article:

Share article via email
Acorda Therapeutics

MS selfā„¢ mobile appAt the 2014 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and the Americas Committee for Treatment and Research in Multiple Sclerosis on May 28-31 in Dallas, Acorda Therapeutics will be demonstrating its award-winning MS selfā„¢ mobile app designed for patients with multiple sclerosis. Acorda promotes the saying, “With MS, Knowledge is Power,” and their MS self app is designed to empower individuals living with multiple sclerosis.

MS self app is part of the MoveOverMS.org initiative from Acorda. “We developed MoveOverMS.org and MS self to help people proactively manage the challenges they face living with multiple sclerosis. We are excited to share these digital tools with the healthcare professionals attending the CMSC/ACTRIMS meeting, providing them with additional resources for their patients,” said Adrian Rabinowicz, Acorda’s Senior Vice President, Clinical Development and Medical Affairs, in a news release. The site contains videos, articles, and downloadable information.

The application is an extension of their web-based tools. MS self app allows 24/7 access to tools such as a thoughts journal, Fact Cards, and a documentation of individual progress. It was recently updated on the iTunes store and is free to download for iPhone and iPad.

[adrotate group=”4″]

Acorda TherapeuticsAcorda Therapeutics was founded in 1995. “Our company’s mission is to improve the lives of people with neurological disorders. Research and development of novel medicines is a core component of our mission, as is providing support to people with multiple sclerosis, their care partners and healthcare team,” said Rabinowicz. In addition to their MoveOverMS.org web source, three FDA-approved therapies are in use to help multiple sclerosis patients, and six clinical-stage and one preclinical therapies are in the pipeline for neurological disease.